CYCC — Cyclacel Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $2.35m
- -$1.03m
- $0.42m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.87 | ||
| Price to Tang. Book | 3.87 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 5.59 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -3952.33% | ||
| Return on Equity | -216.31% | ||
| Operating Margin | -6060.24% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 0.42 | n/a | n/a | 22.87% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.
Directors
- Christopher Henney NEC (80)
- Spiro Rombotis PRE (62)
- Paul Mcbarron CFO (60)
- Mark Kirschbaum SVP (60)
- Samuel Barker IND (78)
- Gregory Hradsky IND (60)
- Brian Schwartz IND
- Lloyd Sems IND (49)
- Robert Spiegel IND (71)
- Karin Walker IND (57)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 5th, 1996
- Public Since
- January 1st, 1996
- No. of Shareholders
- 11
- No. of Employees
- 12
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 1,318,257
- Address
- 200 Connell Dr Ste 1500, BERKELEY HEIGHTS, 07922-2811
- Web
- https://cyclacel.com/
- Phone
- +1 9085177330
- Auditors
- RSM US LLP
Upcoming Events for CYCC
Cyclacel Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2024 Cyclacel Pharmaceuticals Inc Earnings Release
Similar to CYCC
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Cyclacel Pharmaceuticals share price?
As of Today at 19:06 UTC, shares in Cyclacel Pharmaceuticals are trading at $1.78. This share price information is delayed by 15 minutes.
How has the Cyclacel Pharmaceuticals share price performed this year?
Shares in Cyclacel Pharmaceuticals last closed at $1.78 and the price had moved by -82.99% over the past 365 days. In terms of relative price strength the Cyclacel Pharmaceuticals share price has underperformed the S&P500 Index by -85.84% over the past year.
What are the analyst and broker recommendations for Cyclacel Pharmaceuticals?
The overall consensus recommendation for Cyclacel Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Cyclacel Pharmaceuticals dividend yield?
Cyclacel Pharmaceuticals does not currently pay a dividend.
Does Cyclacel Pharmaceuticals pay a dividend?
Cyclacel Pharmaceuticals does not currently pay a dividend.
When does Cyclacel Pharmaceuticals next pay dividends?
Cyclacel Pharmaceuticals does not currently pay a dividend.
How do I buy Cyclacel Pharmaceuticals shares?
To buy shares in Cyclacel Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cyclacel Pharmaceuticals?
As of the previous close price of $1.78, shares in Cyclacel Pharmaceuticals had a market capitalisation of $2.35m.
Where are Cyclacel Pharmaceuticals shares listed?
Here are the trading details for Cyclacel Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CYCC
What kind of share is Cyclacel Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Cyclacel Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cyclacel Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Cyclacel Pharmaceuticals is $16.00. That is 798.88% above the last closing price of $1.78.
Analysts covering Cyclacel Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$13.38 for the next financial year.
What is the trend in the Cyclacel Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cyclacel Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -84.13%.
As of the last closing price of $1.78, shares in Cyclacel Pharmaceuticals were trading -64.32% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cyclacel Pharmaceuticals PE Ratio?
The Cyclacel Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.78.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals' management team is headed by:
- Christopher Henney - NEC
- Spiro Rombotis - PRE
- Paul Mcbarron - CFO
- Mark Kirschbaum - SVP
- Samuel Barker - IND
- Gregory Hradsky - IND
- Brian Schwartz - IND
- Lloyd Sems - IND
- Robert Spiegel - IND
- Karin Walker - IND